Tromsø, 08 October, 2020: ArcticZymes AS, a subsidiary of ArcticZymes
Technologies ASA (OSE:AZT), announces that it has entered into a supply and
distribution agreement with precision medicine company Jiangsu Simcere
Diagnostics, Nanjing, China for the supply of Heat-Labile Salt Active Nuclease
(HL-SAN) to be used in the development and manufacturing of Simcere's sequencing
assays.
HL-SAN is a critical component of Simcere Diagnostics' infectious disease
metagenomic assays. In particular, the nuclease supplied by ArcticZymes plays a
key role in the removal of host DNA from the sample. This results in a
streamlined and efficient sample preparation process that reduces background
noise from the assay. Metagenomic assays are extremely sensitive to competing
background noise. Fortunately, HL-SAN's unique capability to interact with salt
provides Simcere the best host DNA removal solution available on the market.
Simcere Pharmaceutical Group, the parent of Simcere Diagnostics, is recognized
as one of the "Top 10 Innovative Pharmaceutical Enterprises in China" and "Top
100 Pharmaceutical Manufacturing Enterprises in China". Simcere has three R&D
centers including Boston in the United States and focuses on oncology, central
nervous system disease, and autoimmune disease therapeutic and diagnostic areas
with a diverse portfolio of products.
ArcticZymes Technologies ASA, CEO, Jethro Holter said:
"We look forward to supporting Simcere Diagnostics in the development and future
commercialization of their innovative sequencing assays as well as other future
technologies. This is just the beginning of a long-term relationship together
where ArcticZymes' novel enzyme technologies and scientific competence will aid
Simcere Diagnostics in marketing best in class sequencing technologies. The
agreement marks the first step for ArcticZymes in becoming a long-term supplier
of its enzymes to commercial partners in China."
Simcere Diagnostics CEO, Yong Ren said:
"Simcere Diagnostics is excited to collaborate with ArcticZymes AS. This global
collaboration not only helps Simcere in the development and commercialization of
its metagenomic products, it also provides our friend ArcticZymes with a market
penetration opportunity to the Chinese market. We plan to work closely in the
future to explore additional means to strengthen our partnership and achieve
additional penetration in China."
For more information, please contact:
ArcticZymes Technologies
Jethro Holter, CEO Tel: +47
46 85 91 46
Email: Jethro.holter@arcticzymes.com
About ArcticZymes AS
ArcticZymes develops, produces and markets novel recombinant enzymes for use in
molecular research, In Vitro Diagnostics (IVD) and therapeutics.
The Company focuses on novel and high-quality enzyme technologies in growth
markets where rapid technological developments are creating a strong demand for
new and improved enzymes. Some of its enzymes' unique features include heat
lability and activity in challenging environments as well as customized,
engineered novel features which can be integrated to power the technologies of
commercial partners.
All ArcticZymes products are ISO13485 certified.
For more information, please visit: www.arcticzymes.com
About Simcere Diagnostics
Founded by Simcere Pharmaceutical Group in 2017, Simcere Diagnostics is a
precision medicine company based in China and led by a team of highly
experienced professionals in medical genomics and informatics. Utilizing various
state-of-the-art technology platforms including Next Generation Sequencing,
Nanopore sequencing, MassARRAY® genotyping, digital PCR, as well as advanced
bioinformatics, Simcere Diagnostics is committed to fulfilling the unmet medical
needs in disease diagnosis, treatment guidance, and progress monitoring via cost
-effective and personalized solutions. Simcere Diagnostics is dedicated to
developing cutting-edge diagnostic products in the clinical areas of cancer,
central nervous system diseases, infectious diseases, pharmacogenomics, and
autoimmune disorders.